Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial by Bush, Ashley I. et al.
Homocysteine-Lowering by B Vitamins Slows the Rate of
Accelerated Brain Atrophy in Mild Cognitive Impairment:
A Randomized Controlled Trial
A. David Smith1,2*., Stephen M. Smith3, Celeste A. de Jager1, Philippa Whitbread1, Carole Johnston1,2,
Grzegorz Agacinski1, Abderrahim Oulhaj1, Kevin M. Bradley4, Robin Jacoby5, Helga Refsum1,2,6.
1Oxford Project to Investigate Memory and Ageing (OPTIMA), University of Oxford, Oxford, United Kingdom, 2University Department of Pharmacology and Department
of Physiology, Anatomy & Genetics, University of Oxford, Oxford, United Kingdom, 3Department of Clinical Neurology, Oxford Centre for Functional Magnetic Resonance
Imaging of the Brain, University of Oxford, Oxford, United Kingdom, 4Department of Radiology and Nuclear Medicine, Oxford Radcliffe Hospitals NHS Trust, Oxford,
United Kingdom, 5University Department of Psychiatry, University of Oxford, Oxford, United Kingdom, 6Department of Nutrition, Institute of Basic Medical Sciences,
University of Oslo, Oslo, Norway
Abstract
Background: An increased rate of brain atrophy is often observed in older subjects, in particular those who suffer from
cognitive decline. Homocysteine is a risk factor for brain atrophy, cognitive impairment and dementia. Plasma
concentrations of homocysteine can be lowered by dietary administration of B vitamins.
Objective: To determine whether supplementation with B vitamins that lower levels of plasma total homocysteine can slow
the rate of brain atrophy in subjects with mild cognitive impairment in a randomised controlled trial (VITACOG, ISRCTN
94410159).
Methods and Findings: Single-center, randomized, double-blind controlled trial of high-dose folic acid, vitamins B6 and B12
in 271 individuals (of 646 screened) over 70 y old with mild cognitive impairment. A subset (187) volunteered to have
cranial MRI scans at the start and finish of the study. Participants were randomly assigned to two groups of equal size, one
treated with folic acid (0.8 mg/d), vitamin B12 (0.5 mg/d) and vitamin B6 (20 mg/d), the other with placebo; treatment was
for 24 months. The main outcome measure was the change in the rate of atrophy of the whole brain assessed by serial
volumetric MRI scans.
Results: A total of 168 participants (85 in active treatment group; 83 receiving placebo) completed the MRI section of the
trial. The mean rate of brain atrophy per year was 0.76% [95% CI, 0.63–0.90] in the active treatment group and 1.08% [0.94–
1.22] in the placebo group (P= 0.001). The treatment response was related to baseline homocysteine levels: the rate of
atrophy in participants with homocysteine .13 mmol/L was 53% lower in the active treatment group (P= 0.001). A greater
rate of atrophy was associated with a lower final cognitive test scores. There was no difference in serious adverse events
according to treatment category.
Conclusions and Significance: The accelerated rate of brain atrophy in elderly with mild cognitive impairment can be
slowed by treatment with homocysteine-lowering B vitamins. Sixteen percent of those over 70 y old have mild cognitive
impairment and half of these develop Alzheimer’s disease. Since accelerated brain atrophy is a characteristic of subjects with
mild cognitive impairment who convert to Alzheimer’s disease, trials are needed to see if the same treatment will delay the
development of Alzheimer’s disease.
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Introduction
In elderly, the brain shows significant progressive atrophy. The
atrophy occurs even in cognitively healthy subjects [1] but is much
accelerated in patients suffering from Alzheimer’s disease [2,3,4,5].
An intermediate rate of atrophy is found in people with mild
cognitive impairment (MCI) [6,7,8,9,10,11]. Since the rate of
brain atrophy is more rapid in subjects with MCI who convert to
Alzheimer’s disease [5], it is important to identify factors that
determine the rate of atrophy since reducing the rate of atrophy is
likely to slow the conversion to Alzheimer’s disease. One such
factor appears to be raised concentrations of plasma total
homocysteine (tHcy). Moderately elevated concentrations of tHcy
have been associated with an increased risk of dementia, notably
Alzheimer’s disease, in many cross-sectional and prospective
studies [12,13,14,15,16]. Raised tHcy is also associated with both
regional and whole brain atrophy, not only in Alzheimer’s disease
[12] but also in healthy elderly [17,18,19,20,21].
The tissue and plasma concentrations of homocysteine are
largely determined by the body’s status of certain B vitamins
(folate, B6 and B12), which are cofactors or substrates for enzymes
involved in homocysteine metabolism [22]. The VITACOG trial
reported here was designed to see if lowering tHcy concentrations
by the administration of high doses of supplementary B vitamins
(folic acid, vitamins B6 and B12) over two years would slow the rate
of atrophy of the brain in elderly subjects with MCI. This group
was chosen because they suffer from modestly increased rate of
atrophy, making it possible to detect significant changes in rate of
atrophy in a relatively small number of subjects followed for
relatively short time. The chosen doses of vitamins lower tHcy
levels by about 30% in populations from countries without
mandatory folic acid fortification of flour [23].
Methods
The study was carried out according to the principles expressed
in the Declaration of Helsinki and was approved by a local NHS
research ethics committee (COREC 04/Q1604/100). Each
subject gave written consent for their participation. The Protocol
for this Trial and supporting CONSORT checklist are available as
supporting information; see Protocol S1 and Checklist S1.
Study protocol
Participants in the Oxford area were recruited between April
2004 and November 2006 through advertisements in the local
newspaper or radio seeking elderly people with concerns about
their memory. The trial has been registered as VITACOG,
‘Homocysteine and B vitamins in cognitive impairment’ ISRCTN
94410159 (http://www.controlled-trials.com/).
Inclusion criteria included: age $70 years; study partner
available as informant, and diagnosis of amnestic or non-amnestic
MCI according to Petersen’s criteria [24]. The diagnosis included
a subjective concern about memory that did not interfere with
activities of daily living, assessed with 4 questions on subjective
memory complaints from the Cambridge Mental Disorders of the
Elderly Examination (CAMDEX) [25] and 5 questions relating to
activities of daily living based on the Cambridge Behavioural
Inventory [26], an objective memory problem assessed with the
‘Telephone interview of cognitive status, modified’ (TICS-M) [27],
a test without a ceiling effect [28], and category fluency [29] based
on previously defined cut-off scores for MCI [28]. Thus, eligible
subjects had a score of 17 – 29 out of a maximum of 39 on TICS-
M. For borderline cases, if TICS-M was .29 but category fluency
,19 or TICS-M word recall #10/20, then subjects were eligible.
Alternatively, if TICS-M was ,17 but category fluency was $19
or word recall was $10/20, then subjects were also eligible. Other
measures to confirm the MCI diagnosis collected at the first visit
were a Mini-mental state examination (MMSE) [30] score of
.24/30 and no evidence of dementia. Further details about the
protocol are in Methods S1 and in Protocol S1.
Exclusion criteria included: a diagnosis of dementia or being
treated with anti-dementia drugs; active cancer; major stroke
within past 3 months; treatment with methotrexate, anti-cancer or
anti-epileptic drugs, or taking folic acid .300 mg/d, pyridoxine
.3 mg/d or vitamin B12 .1.5 mg/d by mouth or any dose by
injection. Those taking B vitamins below these doses were allowed
to continue during the trial.
Subjects with MCI who also fulfilled entry criteria and gave
written consent, were randomised to either a treatment group or a
placebo group. Centralised telephone randomization by indepen-
dent statisticians was used with full allocation concealment and
minimization for age, gender, baseline TICS-M score and consent
for MRI. Tablet containers were labelled only with the name of
the trial and the allocated concealment number and the
participants, care partners, and all staff directly involved in the
trial were blinded to interventions during the period of the trial.
The treatment group received oral TrioBe PlusH (Meda AB/Recip
AB, Box 906, Pipers va¨g 2A, SE-170 09 Solna, Sweden) containing
0.8 mg folic acid, 0.5 mg cyanocobalamin and 20 mg pyridoxine
HCl, or a placebo tablet (see Methods S1). The treatment period
was 2 years. Each participant received their study medication at
first visit and by post at 6-monthly intervals. For those who
consented to the MRI scans, the tablets were dispensed on the day
of the first scan. At the second visit, or the second MRI scan,
participants handed back the tablet bottles. Blood sampling and
biochemical assays are described in Methods S1.
MRI scans
Volumetric cranial MRI scans both at baseline and after 2 years
were carried out on a 1.5T MRI system (Sonata; Siemens Medical
Solutions, Erlangen, Germany) at the Oxford Centre for Clinical
Magnetic Resonance Research. The protocol was T1-weighted
acquisition, gradient echo (FLASH-Fast Low angle shot) 3D
acquisition with 1 mm isotropic voxels Flip angle 19 degrees
TR=12 ms TE=5.65 ms; 208 slices per slab with 1 slab acquired
in coronal orientation, 1 average. This was repeated three times
and averaged after acquisition and cross-repeat alignment.
A fully automated, quantitative method, SIENA, was used to
derive the rate of whole brain atrophy per year. SIENA is accurate
with high robustness [31]. The rate of change is estimated from
two MR images taken at different time points. SIENA automat-
ically segments brain from non-brain in each image, and estimates
the external surface of the skull in each image. The two brain
images are registered, while using the skull images to constrain
scaling and skew; this corrects for changes in imaging geometry
over time. Brain surface points (including ventricle surfaces) are
found using the registered brain images to sub-voxel accuracy, and
the surface motion estimated on the basis of these points. The
mean perpendicular edge motion across the entire brain surface
produces a change image that can be converted into estimates of
rate of atrophy reflecting changes in both grey and white matter
[31]. In this study, we have used the rate of atrophy per year based
on measurements two years apart.
A cross-sectional method (SIENAX) was used to estimate
normalized brain volume from a single image, using the skull to
normalize spatially, with respect to a standard image [31]. A
participant’s normalized brain volume at baseline was used as a
covariate in some of the analyses.
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Statistical Analysis
Power estimates for the trial were based on existing data using
the same MRI procedure and SIENA in 49 elderly with MCI from
OPTIMA where the mean (SD) rate of shrinkage was 0.74 (0.27)%
per year. Similar values were reported by Jack et al. [5]. To detect
a 20% reduction in rate, we needed 70 subjects per group for 90%
power, or 50 subjects per group for 80% power at alpha= 0.05
(two tailed). On the basis of a drop-out rate or failed MRI of
,20%, we aimed for a sample size of 90 in each arm at the start of
the study. This study was not powered for assessment of cognitive
effects (to be reported separately).
Variables were treated as normally distributed in the population
unless otherwise found by standard tests, in which case they were
log transformed. Those values that were log transformed are
shown in Table S1.
The efficacy analyses were performed on the basis of the
intention-to-treat principle, and included all randomly assigned
subjects who received at least one dose of the assigned study
medication. The main outcome measure was to determine
whether the rate of atrophy of the whole brain per year over the
trial period differed between the treatment groups, using the
SIENA method. Since the requirement was that the subjects had
both a baseline and a follow-up MRI, we conducted an
intention-to-treat analysis for the main outcome in the subgroup
that completed both MRI scans (n = 168). Plasma vitamin
response was reported from the same group. Serious adverse
events were evaluated in the total intention-to-treat group
(n = 266/271).
We also analyzed the rate of atrophy according to biological
compliance, defined by changes in plasma vitamin concentrations
over two years, using the following cut-off values for the two
groups. In the active treatment group compliant subjects were
defined as those who responded with increases from baseline to
follow-up in plasma folate of .10 nmol/L and in vitamin B12 of
.150 pmol/L. In the placebo group compliant subjects were
defined as those who showed increases of #10 nmol/L in folate
and #150 pmol/L in vitamin B12. The other subjects were
classified as biologically non-compliant subjects.
Age was considered a confounding variable for the primary
endpoint [3]. A variety of other covariates that might be associated
with rate of brain atrophy [5,32,33,34,35,36] or with B vitamin
status [37] were identified before the study was analysed. The
assessment of the influence of covariates included a univariate
procedure (unpaired t test or Pearson’s correlations), followed by
age-adjusted analyses. If any variable was significant in the age-
adjusted analyses at P,0.10, it was included in subsequent
analyses. Differences between intervention groups were tested
using the Chi square test for categorical variables and the t test or
analysis of variance for continuous variables.
Pre-specified secondary outcomes included cognitive and
depression scores (to be reported separately), serious adverse
events, withdrawals, compliance and the changes in biochemical
markers. Pre-specified subgroup analyses using ANOVA (categor-
ical variables) or linear regression (continuous variables) included
the influence of baseline vitamin markers on treatment effect, the
rate of atrophy in the two groups after evaluation of biochemical
compliance, association between change in biochemical markers
(independent of treatment code) and rate of atrophy, and rate of
atrophy in relevant subgroups . Reported P values are 2-sided and
unadjusted for multiple comparisons; P ,0.05 was regarded as
statistically significant. SPSS for Macintosh (16th ed.) or Windows
(17th ed.), (SPSS Inc, Chicago, IL; USA) was used for the statistical
analyses.
Results
Participants
The flow of participants through the study is shown in Fig. 1.
From a total of 646 participants assessed through the initial
telephone interview, 292 fulfilled the entry criteria. A total of 271
subjects was randomized, but five subjects did not start treatment
and are excluded from the intention-to-treat analyses. The
numbers lost to follow-up were similar in both groups, with 110
and 113 completing the 24 month trial in the active group and
placebo group, respectively. The primary analysis included only
those subjects where we had technically good MRI scans at
baseline and at follow-up, i.e., 85 in the active group and 83 in the
placebo. The baseline characteristics in the groups were similar
(Tables 1 and 2). The mean (SD) period between MRI scans was
24.3 (0.7) months.
Adherence, and biological vitamin response
Adherence, assessed by counting returned tablets, was overall
good in both groups: More than 78% of participants used at least
75% of their medication. Adherence was also assessed by
measuring plasma vitamins and related compounds (Table 2). In
the active treatment group, geometric mean (95% CI) of plasma
folate increased by nearly 270% and plasma vitamin B12 doubled.
In contrast, the corresponding changes for the placebo group were
modest increases of 3% and 10%, respectively. Plasma tHcy
decreased by 22.5% in the active group, but increased by 7.7% in
the placebo group. Using criteria for biological compliance based
on changes in folate or vitamin B12, as defined in Methods, we
found that 17 out of 83 (20.5%) of the placebo group had taken
supplementary folic acid or vitamin B12. In the active treatment
group, 14 out of 84 subjects (16.7%) with blood samples available
did not take, or did not absorb, the vitamins, at least in the period
prior to the second blood sampling (at 24 months). Thus,
altogether 136 subjects are defined as biologically compliant out
of the 167 in the MRI sub-study where plasma samples were
available.
Factors associated with rate of atrophy in placebo group
Several factors that might influence the rate of atrophy, tHcy
or B vitamin status and/or cognition were pre-specified and
tested for their effects; these are shown in Tables S1 and S2. Age
was strongly associated with rate of brain atrophy (r = 0.32,
P,0.01) and so all subsequent analyses were adjusted for age.
Neither sex, smoking, BMI, alcohol consumption, APOE4 status
nor MTHFR 677C.T polymorphism was associated with the
rate of atrophy (P.0.1 for all, adjusted for age). For the
continuous variables, rate of atrophy was significantly associated
with baseline log tHcy (partial r = 0.41, P,0.001) and with
plasma creatinine (partial r = 0.22, P=0.049). Borderline associ-
ations were observed for diastolic blood pressure (partial
r =20.21, P=0.054), and for initial brain volume (partial
r =20.19, P=0.092). The latter four variables were included in
subsequent adjusted analyses.
Main outcome: rate of atrophy
Treatment with B vitamins for 24 months significantly slowed
the rate of brain atrophy. After adjustment for age, the rate of
brain atrophy per year was 29.6% less in the active treatment
group (0.76% [95% CI, 0.63–0.90]) compared to the placebo
group (1.08% [0.94–1.22], P=0.001). Additional adjustment for
the above-mentioned variables marginally changed the decrease to
27.1% (respective rates of atrophy: 0.78% [0.64–0.91] and 1.07%
[0.94–1.21], P=0.003). If we confined the analysis to the
Homocysteine and Brain Atrophy
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Figure 1. Participant Flow in the trial.
doi:10.1371/journal.pone.0012244.g001
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biologically compliant subjects (n = 136), the effect of treatment
was slightly greater with a reduction in atrophy rate of 31.1% in
the active treatment group (rate of atrophy: 0.73% [0.57–0.88])
compared to the placebo group (1.06% [0.90–1.22], P=0.004
after multi-adjusted analysis). There was no effect of treatment on
the 31 subjects who were categorised as biologically non-compliant
(P=1.00), probably because they started with a lower tHcy at
baseline and, in those receiving B vitamins, the tHcy reduction was
a modest 13%. Furthermore, the number of subjects is too small to
detect an effect.
Secondary outcomes
As stated above, the subjects responded to the treatment as
expected in terms of plasma vitamin response (Table 2).
Furthermore, we found a significant interaction between baseline
tHcy level and treatment effect (log tHcy x treatment, P=0.001).
In the placebo group, tHcy at baseline showed a striking positive
relationship to the rate of atrophy (R2= 0.24), whereas this
association was absent in the active group (Fig. 2). Neither baseline
folate nor the vitamin B12 markers showed such a relation.
We also examined atrophy in relation to the change in tHcy,
folate and vitamin B12 markers from baseline to follow-up
(Table 3). Rate of atrophy was significantly associated with the
change in tHcy, and inversely with change in holoTC and TC
saturation. Furthermore, when we confined the analyses to the
biologically compliant subjects, the effects became stronger and
change in folate and vitamin B12 also became significant. There
was no association with change in cystathionine levels (a marker of
vitamin B6 status). Thus, the greater the improvement in folate or
vitamin B12 status, the slower was the rate of atrophy. Conversely,
Table 1. Baseline characteristics of the participants completing the MRI protocol.
Characteristics Placebo group (n =83) Active treatment groupa (n =85)
Mean or n SD or % Mean or n SD or %
Age, years 76.2 4.5 77.0 5.2
Women, n (%) 52 62.7 50 58.8
Years of education 14.8 3.5 14.3 3.6
Body Mass Index, kg/m2 b 26.6 4.2 25.3 3.4
Systolic blood pressure, mmHg 147 19 148 25
Diastolic blood pressure, mmHg 80 11 80 11
TICS-M score 24.8 2.7 24.9 2.8
MMSE score 28.3 1.5 28.3 1.8
Initial brain volume, mL 1376 71 1387 86
Depression score (GDS) c 7.5 5.2 5.6 4.0
Ever-smoker, n (%) 43 51.8 38 44.7
No ankle vibration sense, n (%) 50 60.2 55 64.7
Hemoglobin, g/L 138 12 138 13
MCV, fL 93.0 4.3 92.3 4.4
Creatinine, mmol/L 97 17 96 18
APOE e4 positive, n (%) 29 34.9 22 25.9
MTHFR 677C.T allele frequency (%) 34.9 34.7
TCN2 776C.G allele frequency (%) 30.1 37.1
Use of B vitamins at baseline, n (%) 17 20.5 14 16.5
Use of fish-oils, omega-3, n (%) 31 37.3 36 42.4
Diabetes any time, n (%) 10 12.05 4 4.7
Use of CVD drugs baseline, n (%) 36 43.4 42 49.4
Use of centrally acting drugs, n (%) 20 24.1 23 27.1
Use of aspirin baseline (%) 28 33.7 26 30.6
Other NSAIDs baseline 12 14.5 18 21.2
Stroke, TIA, MRI infarct at baseline 15 18.1 13 15.3
History of MI baseline 6 7.3 6 7.1
Alcohol consumption (units/week) 7.2 d 8.6 8.2 9.3
Abbreviations: APOE, gene for apolipoprotein E; CVD, cardiovascular disease; GDS, Geriatric Depression Scale; MCV, mean red cell volume; MI, myocardial infarct; MMSE,
mini-mental state examination; MTHFR, gene for methylenetetrahydrofolate reductase; NSAID, non-steroidal anti-inflammatory drug; TIA, transient ischemic attack; TICS-
M, telephone interview of cognitive status, modified. Except where indicated by superscript letters, none of the factors differed between the placebo and active
treatment groups.
aActive treatment group received daily supplements of folic acid (0.8 mg), vitamin B12 (0.5 mg) and vitamin B6 (20 mg) for 24 months.
bP= 0.022;
cP= 0.009;
dExcluding one high outlier.
doi:10.1371/journal.pone.0012244.t001
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Table 2. Folate and vitamin B12 markers in plasma before and after 2 years of intervention in the MRI subgroup.
Placebo group Active treatment groupa
N
Geometric
mean 95% C.I. N
Geometric
mean 95% C.I. P valueb
tHcy Before 83 11.27 (10.58–12.00) 85 11.25 (10.58–11.97) 0.974
(mmol/L) After 83 12.14 (11.40–12.93) 84 8.72 (8.29–9.17) ,0.001
P valuec ,0.001 ,0.001
Folate (nmol/L) Before 83 24.2 (21.4–27.5) 85 22.4 (19.4–25.9) 0.428
After 83 24.9 (21.4–29.1) 84 82.1 (74.6–90.4) ,0.001
P valuec 0.695 ,0.001
Vitamin B12 (pmol/L) Before 83 333 (310–357) 85 330 (303–360) 0.891
After 83 366 (335–400) 84 672 (626–722) ,0.001
P valuec 0.018 ,0.001
HoloTC (pmol/L) Before 83 68 (61–76) 85 63 (55–72) 0.406
After 83 73 (65–82) 84 182 (162–204) ,0.001
P valuec 0.116 ,0.001
TC saturation (%) Before 83 7.35 (6.54–8.25) 85 6.65 (5.72–7.73) 0.306
After 83 7.17 (6.26–8.21) 84 20.42 (18.21–22.90) ,0.001
P valuec 0.648 ,0.001
Cystathionine Before 83 0.303 (0.273–0.337) 85 0.265 (0.237–0.295) 0.082
(mmol/L) After 83 0.350 (0.311–0.395) 84 0.215 (0.196–0.235) ,0.001
P valuec 0.002 ,0.001
Abbreviations: HoloTC, holotranscobalamin; TC saturation, ratio of holoTC to total TC; tHcy, plasma total homocysteine.
aActive treatment group received daily supplements of folic acid (0.8 mg), vitamin B12 (0.5 mg) and vitamin B6 (20 mg) for 24 months.
bStudent’s t-test for unpaired samples,
cStudent’s t-test for paired samples.
doi:10.1371/journal.pone.0012244.t002
Figure 2. Atrophy rate by baseline homocysteine. Linear regression lines with 95% mean prediction intervals. R2 for placebo group (n = 83) was
0.242 (P,0.001); for the treatment group (n = 85) R2 was 0.001 (P= 0.74). The x-axis is a logarithmic scale labelled with linear values.
doi:10.1371/journal.pone.0012244.g002
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those subjects whose folate or vitamin B12 status declined were at
increased risk of atrophy, illustrated in Fig. 3, using tHcy as a
marker. A striking example of the effect of changes in tHcy
concentrations on brain atrophy over two years is shown in Fig. 4,
which illustrates subtraction cranial MRI scans from a participant
in the placebo group whose tHcy concentration increased (Fig. 4A),
and from a member of the active treatment group whose tHcy
concentration decreased (Fig. 4B). Both subjects started with
similar raised tHcy concentrations but the participant taking
placebo showed a further increase in tHcy over the two years,
while the participant taking active treatment showed a marked fall
in tHcy over this period. The rate of atrophy was more than 5-
times slower in the participant taking B vitamins than in the
subject taking placebo.
The effects in various subgroups are shown in Table S2. There
were no significant interactions between treatment and the
following variables: age, sex, category of MCI, normalized initial
brain volume, hypertension, use of non-aspirin NSAIDs, smoking,
creatinine, APOE4 and MTHFR 677C.T. Diabetes was associ-
ated with increased rate of atrophy (P=0.014) and this effect was
apparently not influenced by treatment, although the interaction
was not significant, possibly because of the small number of
subjects (n = 4). In line with the interaction with baseline tHcy
described above, in participants with baseline tHcy below the
median, the active treatment was associated with 11.2% slower
rate of atrophy, whereas those with baseline tHcy above median
showed a 43.0% reduction in atrophy (Pinteraction = 0.019). When
tHcy was further divided into quartiles, there was no effect of
treatment in those in the lowest quartile (tHcy #9.5 mmol/L),
whereas there was a 53.3% reduction in rate of atrophy in those in
the 4th quartile of tHcy (.13.0 mmol/L) treated with B vitamins
vs. placebo (Ptreatment = 0.001; PtHcy = 0.139; Pinteraction = 0.023).
An interaction between treatment category and a history of stroke
or TIA at baseline was found: those in the placebo group with a
previous event had an atrophy rate per year of 1.76%[1.31–2.21]
compared with 1.01% [0.86–1.15] for those without an event.
Those in the active treatment group had rates of 0.74% [0.35–
1.14] and 0.77% [0.63–0.91] (Ptreatment,0.001; Pstroke = 0.028;
Pinteraction = 0.014), respectively. Thus, the increased rate in the
stroke subjects was slowed down by the vitamin treatment. This
interaction with stroke was no longer significant (P=0.098) when
subjects with silent infarcts seen on MRI were included, although
there was still a significant effect of stroke overall on atrophy rate
(P=0.025). Regular use of aspirin showed a tendency to interact
with treatment (Ptreatment = 0.021; Paspirin = 0.19; Pinteraction =
0.052); in those taking aspirin the treatment appeared less
effective. A subset of participants reported taking multivitamin
supplements containing B vitamins prior to the trial (Table 1) and
in these there was a significant interaction with treatment
(P=0.034) such that active treatment was no longer effective.
This lack of effect may be related to their low tHcy (geometric
mean 9.9 [9.0–10.9] mmol/L), high folate (38.1 [30.9–46.9] nmol/
L) and vitamin B12 (388 [343–441] pmol/L) already at baseline.
This baseline concentration of tHcy is close to that described
above (9.5 mmol/L) where we found no effect of treatment.
Although the study was not powered to detect an effect of
treatment on cognition (findings to be reported separately), in a
post hoc analysis, we noted that final cognitive test scores were
correlated to the rate of atrophy. Multiple linear regression showed
that the main factors that significantly determined the MMSE
score at the end of the study were baseline MMSE score (partial
Table 3. Associations of rate of atrophy with changes in
plasma biochemical markers upon treatmenta.
Change in As randomisedb Compliant subjectsc
Marker Partial rd Partial rd
(n=166) P (n = 134) P
tHcy 0.19 0.017 0.25 0.004
Folate 20.13 0.096 20.29 0.001
Vitamin B12 20.05 0.516 20.27 0.002
HoloTC 20.20 0.011 20.25 0.004
TC saturation 20.22 0.004 20.25 0.005
Cystathionine 0.06 0.472 0.03 0.708
Abbreviations: HoloTC, holotranscobalamin; TC saturation, ratio of holoTC to
total TC; tHcy, plasma total homocysteine.
aActive treatment group received daily supplements of folic acid (0.8 mg),
vitamin B12 (0.5 mg) and vitamin B6 (20 mg) for 24 months.
bAll subjects in the MRI subgroup that started treatment and with baseline and
follow-up blood sampling.
cThe actively treated subjects where classed as compliant if they had an
increase from baseline to follow-up in plasma folate of .10 nmol/L and in
vitamin B12 of.150 pmol/L; the placebo subjects were classed as compliant if
the increase from baseline to follow-up was #10 nmol/L in plasma folate and
#150 pmol/L in plasma vitamin B12. dAdjusted for age, baseline diastolic
blood pressure, baseline creatinine, initial brain volume and log baseline tHcy.
doi:10.1371/journal.pone.0012244.t003
Figure 3. Atrophy rate by change in plasma total homocysteine
over a two year period. Subjects in this analysis were a subset (66 in
placebo; 70 in the active treatment) who showed biochemical evidence
of good compliance (see Table 3). Linear regression with 95% mean
prediction intervals, adjusted for age at baseline; partial r = 0.22,
P= 0.011. The x-axis is a logarithmic scale labelled with linear values.
doi:10.1371/journal.pone.0012244.g003
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r = 0.42, P,0.001), rate of brain atrophy (partial r =20.36,
P,0.001) and age (partial r =20.20, P=0.01); the adjusted R2
was 0.33. The same factors determined the final TICS-M score:
baseline TICS-M (partial r = 0.39, P,0.001), atrophy rate (partial
r =20.36, P,0.001), and age (partial r =20.27, P,0.001); the
adjusted R2 was 0.39. Thus, brain atrophy rate appears to be a
major determinant of cognitive decline in this population.
Safety outcomes in the whole cohort
The overall B vitamin status was very good in the whole cohort
of 266 participants. Only 7 participants (2.6%) had plasma folate
concentrations of ,7 nmol/L and 6 (2.3%) had vitamin B12
concentrations of ,150 pmol/L at baseline. Since the vitamin
analyses were done after the trial ended, these subjects, although
classified as vitamin deficient, were not treated medically unless
diagnosed by their GP.
Altogether 48 subjects were lost to follow-up in the whole trial,
28 (five immediately before starting taking tablets) in the active
group and 20 in the placebo group. Reasons for withdrawal are
shown in Table S3. There were no significant safety issues and no
significant differences in adverse events, except that there were
fewer subjects in the active treatment group who showed a loss of
vibration sense (Table S3). The time to dropout was shorter in the
active group, even after excluding the immediate dropouts.
Discussion
B vitamin treatment led to a difference in final tHcy
concentration of 31.7% compared with the placebo, and was
accompanied by a reduction in the rate of brain atrophy of almost
30%. No safety issues were found, so it can be concluded that high
doses of B vitamins can be used to reduce the rate of atrophy of the
brain in elderly people with MCI.
In agreement with the prior hypothesis, the treatment effect was
greatest in those with the highest baseline level of tHcy, with a
reduction in atrophy rate of 53% in those in the top quartile of
tHcy (.13.0 mmol/L). Notably, there was no effect of treatment
on atrophy in those in the bottom quartile (#9.5 mmol/L). The
observation in the placebo group that the rate of atrophy was
related to the baseline concentration of tHcy is consistent with,
and may explain, a number of cross-sectional studies reporting
that regional brain atrophy is related to tHcy [17,18,19,20,21].
The results also fit with our earlier finding that raised tHcy
predicts the rate of shrinkage of the medial temporal lobe in
patients with Alzheimer’s disease [12]. In contrast, in the group on
active treatment there was no relationship between baseline tHcy
and the rate of atrophy. It is tempting to suggest that this finding is
consistent with the view that raised homocysteine is a direct cause
of the atrophy. However, it does not exclude that tHcy is only a
marker for low-normal levels of the vitamins, which are themselves
the causal factors.
Our previous observational study on another elderly cohort in
OPTIMA showed that low-normal baseline levels of vitamins B12
were associated with a more rapid rate of atrophy, whereas folate
levels were unrelated [36]. In the present study, we found that an
increase in either vitamin B12 status or in folate status was
associated with a reduced rate of atrophy. Thus, from the present
data we cannot decide which of these two vitamins is the most
important. The lack of association of atrophy with the change in
cystathionine levels, a marker of vitamin B6 status [38], may
indicate that vitamin B6 is less important as a determinant. It is
noteworthy that a cross-sectional study found that supplementary
intake of vitamin B6 or of vitamin B12, but not of folate, was
associated with greater regional gray matter volumes in an elderly
cohort [39].
Possible therapeutic implications
We have shown that treatment for two years with B vitamins
markedly slows the accelerated rate of atrophy in people with
MCI. This study was carried out in the UK, where voluntary
fortification of foods with folic acid is permitted but where there is
no mandatory fortification. The effect of treatment was dependent
on baseline tHcy, with those in the upper three quartiles, i.e.
(A) (B) 
Figure 4. Selected subtraction MRI scans. The images are from the baseline scan with colour superimposed to show the brain tissue change
over the following two years. Colours show expansion (red/yellow) or contraction (blue/light blue) of the brain of 0.3 to 1.0 mm, with the lightest
colour indicating the biggest change. (A) Subtraction image of female participant in the placebo group, age 79 years, with baseline tHcy of 22 mmol/
L, whose tHcy concentration increased by 8 mmol/L over two years. Atrophy rate was 2.50% per year. Atrophy most strongly appears here as
enlargement of the ventricles. (B) Subtraction image of female participant in active treatment group, age 72 years, with baseline tHcy of 24 mmol/L at
baseline, whose tHcy concentration decreased by 12 mmol/L over two years. Atrophy rate 0.46% per year. There is no clear visible pattern of atrophy.
doi:10.1371/journal.pone.0012244.g004
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.9.5 mmol/L, showing a significant slowing of atrophy upon
treatment compared with those in the lowest quartile. In the USA,
which has mandatory fortification, 13.6% of those $60 years-old
had tHcy concentrations .13 mmol/L in 2003-4 [40], a level at
which we found a .50% reduction in the rate of atrophy upon
treatment with high doses of B vitamins. The median tHcy
concentration in those $60 years-old in the USA is 10.1 mmol/L,
suggesting that a substantial proportion of those with MCI could
benefit from the intervention. The prevalence of MCI is between
14% and 18% in those over 70 years-old [24,41], which means
that about 5 million people in the USA and 14 million in greater
Europe suffer from this condition. Since approximately half of
those with MCI convert to Alzheimer’s disease or to another form
of dementia within 5 years [42], there is an urgent need to identify
treatments that will slow down or prevent the conversion [43]. The
outcome of the VITACOG trial indicates that treatment with
homocysteine-lowering B vitamins might be one approach to
meeting this challenge,
This study was designed to detect an effect of treatment on
the rate of atrophy and was not powered to detect effects of
treatment on cognitive test scores. Nonetheless, we consider that
the findings are relevant to cognitive decline in people with
MCI. First, in studies over longer periods (up to 5 years) it has
been found that the rate of whole brain atrophy in MCI is
correlated with cognitive decline in several tests, including the
MMSE [5]. Second, when we looked for significant predictors of
the final cognitive test score, the rate of atrophy was one of the
three main factors determining the final MMSE and TICS-M
scores. Third, two other randomised controlled trials of
homocysteine-lowering treatments have shown effects on
cognition: a trial in which normal participants with baseline
tHcy levels .13 mmol/L were treated with folic acid (0.8 mg/d)
for three years showed a beneficial effect on several cognitive
tests [44]. An 18-month trial of high doses of the same three
vitamins used here showed a slowing of cognitive decline in
patients with mild Alzheimer’s disease, although not in patients
with moderate Alzheimer’s disease [45]. The latter result
indicates that homocysteine-lowering may have to be targeted
at those with early stages of Alzheimer’s disease. Since the rate
of brain atrophy is more rapid in subjects with MCI who
convert to Alzheimer’s disease [5], it is possible that high doses
of folic acid, vitamins B6 and B12 might slow the conversion
from MCI to Alzheimer’s disease. Clinical trials to test this
hypothesis are warranted.
Strengths and limitations
A particular strength of the study is that we used a highly
sensitive and accurate tool for assessment of brain atrophy, i.e.,
MRI and the SIENA protocol. Notably, the SIENA analysis was
carried out on MRI data derived from the average of three T1
volumetric scans at each time point, so providing a high degree of
accuracy. Another strength was the measurement of vitamins and
their markers, which made it possible to show that the baseline
tHcy concentration is a key determinant of the rate of atrophy and
of the response to treatment. In our study, brain atrophy was
among the strongest determinants of MMSE and TICS-M at the
end of the study, supporting the view that assessment of atrophy
rate may be a useful tool in cognitive studies. The study has,
however, some limitations. First, we used combination of the three
B vitamins, so we cannot identify whether they are all required or
if one is more important. Second, this trial was powered to detect
change in rate of atrophy, not cognition; even so we observed a
strong association between atrophy rate and cognition. A
subsequent report will describe the cognitive results in more
detail. Finally, although some of the findings in subgroup analyses
appear quite striking, for example in the stroke or diabetes groups,
or those taking aspirin, these results should be interpreted with
caution because of the small sample size and lack of biological
explanation for the interaction. The importance of these findings
will be in relation to future trials. There is every reason to include
those who have had a previous stroke or subjects with high
creatinine. We obviously need more data on those using aspirin. In
subjects already taking oral supplements of B vitamins, or with
good plasma tHcy and B vitamin status, the effect may be limited,
but it should be investigated whether subgroups could benefit from
even higher intakes, as appeared to be the case for those with mild
AD and with lower levels of tHcy than in our cohort [45].
Conclusions
We show that a simple and safe treatment that targets
homocysteine can slow down the accelerated rate of brain atrophy
found in mild cognitive impairment. Although this is relatively
small trial, it has provided useful data for planning future studies,
whether those will focus on brain atrophy, cognitive decline, or
age-related conditions where brain atrophy will be included as part
of the assessment.
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